Table 33

From: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O172)

 

Number of patients

Median PFS, months

 

≥CR rate, %

 
 

RVd-alone

RVd+ASCT

RVd-alone

RVd+ASCT

HR (95% CI)

RVd-alone

RVd+ASCT

OR (95% CI)

ITT

365

357

46.2

67.5

1.53 (1.23–1.91)

42

47

0.82 (0.61–1.12)

Race

        

 White

268

272

44.3

67.2

1.67 (1.29–2.15)

42

51

0.68 (0.47–0.96)

 Black

66

66

NR

61.4

1.07 (0.61–1.89)

45

30

1.91 (0.89–4.18)

BMI

        

 <25

80

81

33.6

NR

2.60 (1.56–4.31)

42

49

0.76 (0.39–1.48)

 25–30

141

127

52.3

64.3

1.24 (0.86–1.80)

44

49

0.82 (0.49–1.37)

 ≥30

136

157

45.8

64.4

1.41 (0.98–2.02)

40

44

0.84 (0.51–1.37)

ISS disease stage

        

 I

178

184

52.0

NR

1.83 (1.32–2.54)

47

53

0.80 (0.52–1.24)

 II

130

134

46.2

62.5

1.38 (0.96–1.96)

36

41

0.81 (0.48–1.38)

 III

49

47

40.3

35.9

1.14 (0.64–2.01)

39

40

0.93 (0.38–2.29)

Cytogenetic risk

        

 High risk

66

66

17.1

55.5

1.99 (1.21–3.26)

36

53

0.51 (0.24–1.07)

 Standard risk

268

274

53.2

82.3

1.38 (1.07–1.79)

43

47

0.87 (0.61–1.24)

  1. *Data not shown for patients with other/missing race (RVd-alone, n = 23; RVd+ASCT, n = 27)
Back to article page